No Data
Hong Kong stocks fluctuated | Pharmaceutical stocks generally declined as the Trump administration launched an investigation into pharmaceuticals, but Institutions remain Bullish on the growth potential of Innovative Drugs.
Pharmaceutical stocks generally fell. As of the time of writing, ASCLETIS-B (01672) dropped 12.64%, trading at 5.46 Hong Kong dollars; ALPHAMAB-B (09966) fell 7.74%, trading at 6.44 Hong Kong dollars; HBM HOLDINGS-B (02142) decreased by 7.31%, trading at 7.1 Hong Kong dollars.
Hong Kong stock movement | JUNSHI BIO (01877) is currently up over 7%. The chairman plans to increase Shareholding by no less than 0.1 billion yuan in shares. The company will release its first-quarter results at the end of the month.
JUNSHI BIO (01877) is currently up over 7%, with a rise of 7.39% at the time of writing, trading at 15.12 Hong Kong dollars, with a transaction amount of 25.8589 million Hong Kong dollars.
Express News | Junshi Biosciences Says Chairman Plans to Boost Holdings in Co a/H-Shares Worth at Least 100 Mln Yuan
JUNSHI BIO (01877.HK) plans to hold a Board of Directors meeting on April 25 to approve the first-quarter performance.
Gelonghui reported on April 10 that JUNSHI BIO (01877.HK) announced that a Board of Directors meeting is scheduled for April 25, 2025 (Friday) to consider and approve the unaudited financial results of the group for the three months ended March 31, 2025.
JUNSHI BIO: DATE OF BOARD MEETING
[Brokerage Focus] China Securities Co., Ltd. is Bullish on the Innovative Drugs Industry which is currently not affected by tariffs.
Jinwu Financial News | China Securities Co.,Ltd. stated that the impact of tariff policies on the Pharmaceutical Industry Chain is quite complex and may still have uncertainties. In the recent tariffs imposed by the USA on China, Pharmaceuticals are not currently involved. At this point, the firm is Bullish on the Innovative Drugs sector, the opportunities for domestic share increases in Medical Devices and Blood Products under autonomous control, and the Traditional Chinese Medicine, pharmacies, and distribution sectors focused on domestic demand, which are not significantly affected by tariffs. In the long run, going abroad should still be an important Global Strategy for pharmaceutical companies, and the firm firmly believes in the incremental opportunities brought by overseas expansion. The firm pointed out that 1) Innovative Drugs: Currently, going overseas mainly involves BD collaborations.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
